Grünenthal acquires testosterone treatment Nebido™ from Bayer |
| July 14, 2022 | July 2022 Bond Updates |
|
Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal's EBITDA in 2023. NebidoTM is the gold standard for the treatment of male hypogonadism associated with testosterone deficiency. It is available to patients... |
| View more at: https://www.prnewswire.com:443/news-releases/grunenthal-acquires-testosterone-treatment-nebido-from-bayer-301586536.html |
| Related News |